Mersana Therapeutics (MRSN) Misses Q3 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts MRSN Hot Sheet
Join SI Premium – FREE
Mersana Therapeutics (NASDAQ: MRSN) reported Q3 EPS of ($0.35), $0.18 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $7.69 million versus the consensus estimate of $7.53 million.
For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- Eagle Financial Services, Inc. (EFSI) Tops Q3 EPS by 5c
- National Bankshares Inc (NKSH) Misses Q3 EPS by 12c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
